Credits: IMDb
“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.
Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.
Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.
However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.
Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”
In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.
There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.
Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.
Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.
If it was not his session, then how did he get ketamine?
Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.
Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.
Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.
Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”
Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.
Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.
He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.
Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”
The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”
The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”
Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.
Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.
He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.
Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”
Five arrests have been made in the case so far.
Credit: AI
Tiny plastic particles in the human body may cause serious heart attacks. A recent study observed that people who had microplastics present in their arteries supplying blood to the heart are more likely to experience severe heart attacks.
The study has raised concerns about the effects of plastic pollution on cardiovascular health.
A new study published in the European Heart Journal has found that people with microplastics present in the arteries supplying blood to the heart were more likely to experience larger and more severe heart attacks, raising concerns about the cardiovascular effects of plastic pollution.
Microplastics are plastic fragments smaller than five millimeters that originate from the breakdown of larger plastic items.
“Micro and nanoplastics are tiny plastic particles that are found virtually everywhere in the environment, including the air we breathe, the water we drink, and many foods we consume,” said Pasquale Paolisso, lead author of the study.
Although microplastics have already been detected in human blood, lungs, brain, and arteries, researchers are still trying to understand their long-term health effects.
Also read: Recovering From A Heart Attack? Avoid These Dangerous Mistakes
In the latest study, researchers analyzed 61 Italian patients who were treated for heart attacks and measured the presence of microplastics in blood collected from the coronary arteries.
Researchers also collected data on whether the patients were smokers and on their exposure to pollution.
“In our study, smoking history was strongly linked to microplastics in the blood. Our findings suggest that smoking might make it easier for micro and nanoplastics to enter the bloodstream via the lungs. Air pollution may act in a similar way,” Dr Emanuele Barbato, an author of the study from Sapienza University of Rome, said.
Scientists detected micro and nanoplastics in 84 per cent of patients who had heart attacks.
In comparison, only 40 per cent of patients with chronic ischemic heart disease and 32 per cent of patients with normal coronary arteries were found to have micro and nanoplastics.
They discovered that patients with higher levels of microplastics tended to have larger areas of heart muscle damage and greater inflammation, suggesting that these particles may be linked to more severe cardiovascular events.
“While the findings do not prove that plastics directly cause heart attacks, they strengthen the growing scientific evidence that plastic pollution is an emerging public health issue deserving serious attention,” said Thava Palanisami,” a plastic researcher at the University of Newcastle in Australia.
The study is built on earlier research published in 2024, which found that patients whose arterial plaque contained microplastics and nanoplastics were more than four times as likely to suffer a heart attack, stroke, or death.
That landmark study was among the first to find that plastics accumulating inside blood vessels could have important clinical consequences.
Scientists believe microplastics may trigger chronic inflammation and oxidative stress, damage the cells lining blood vessels, and make fatty plaques in arteries more unstable. This could increase the likelihood of heart attacks.
Credit: AP
Almost a year after the last Senate-confirmed director of the US Centers for Disease Control and Prevention (CDC), was fired for backing science and vaccines, President Donald Trump has nominated Dr. Erica Schwartz to head the agency, making her his third CDC nominee in less than two years.
Appearing before the Senate Committee on Health, Education, Labor, and Pensions (HELP) for her confirmation hearing on Wednesday, Schwartz pledged to restore public trust in the CDC through transparency and evidence-based decision-making.
However, she also faced pointed questions about vaccine policy, scientific independence, and whether she would resist pressure from Health Secretary Robert F. Kennedy Jr.
Schwartz highlighted her military background and said restoring confidence in public health institutions would be her top priority.
"If confirmed, my first priority will be restoring trust in public health institutions through radical transparency and unwavering scientific integrity," she said.
"As CDC director, my sacred responsibility is to provide the American people with public health guidance that is clear, honest, and evidence-based. I will never betray science," she added.
Schwartz previously served as deputy US surgeon general during Trump's first administration and held the rank of rear admiral in the US Coast Guard.
Dr. Erica Schwartz is a physician with an extensive background in medicine, public health, engineering, and law. She holds a medical degree (MD), a Master of Public Health (MPH) in epidemiology, a law degree, and a degree in biomedical engineering.
Before being nominated to lead the CDC, Schwartz held several senior public health and military leadership roles, including:
Throughout the hearing, Schwartz repeatedly expressed support for vaccines, including mRNA COVID-19 vaccines, and strongly endorsed vitamin K injections for newborns to prevent life-threatening bleeding.
She also acknowledged that scientific evidence does not support a link between vaccines and autism, while arguing that more research is needed to better understand the rising prevalence of autism.
"We owe it to the American people to figure out why one in 30 children now has autism," she said.
Schwartz stated that she did not believe either President Trump or Health Secretary Kennedy would ask her to take actions that would harm public health or violate the law.
She also said she was unaware of Kennedy's decision to cancel nearly $500 million in mRNA vaccine contracts and was unfamiliar with reported cuts to smoking cessation and food safety programmes.
Although many observers consider Schwartz a qualified nominee with mainstream public health credentials, some experts said her testimony did not provide enough reassurance that she would independently defend scientific evidence if political pressure arose.
Dr. Jeanne Marrazzo, chief executive of the Infectious Diseases Society of America, said she wanted stronger commitments to evidence-based science from leaders overseeing the nation's top public health institutions.
The hearing also renewed criticism of Health Secretary Robert F. Kennedy Jr.'s handling of the CDC.
Several Democratic senators, including Sen. Bernie Sanders, argued that former CDC director Dr. Susan Monarez was removed because she resisted Kennedy's vaccine policies.
"Dr. Monarez, to her credit, stood up for science, public health, and for the scientific method. Frankly, she stood up for protecting the well-being of the American people, and that was the reason that she was fired," Sanders said.
If confirmed by the Senate, Schwartz would replace Dr. Jay Bhattacharya, who’s been serving as acting CDC director since February.
Credit: AI
A new Phase II clinical trial has found that a carefully formulated cannabis-based treatment may help alleviate agitation in people with advanced dementia. The findings offer hope for patients and caregivers who face one of the most distressing symptoms of the disease.
The findings are a result of the LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) trial, that was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London.
Researchers say the treatment, which combines purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in an oral formulation, showed significant improvements compared to a placebo.
The multicenter, randomized, double-blind, placebo-controlled Phase II study enrolled 120 hospice-eligible adults with Alzheimer's disease or other forms of dementia experiencing significant agitation.
Participants received either the THC/CBD formulation or a placebo for 12 weeks. Researchers assessed agitation using the Cohen-Mansfield Agitation Inventory (CMAI) along with clinician evaluations of behavioral improvement.
According to the trial results, participants in the cannabis treatment group experienced significantly greater reductions in agitation than those given a placebo.
Clinician assessments showed improvement in 83.9% of treated participants after two weeks, compared with 30.5% in the placebo group.
By 12 weeks, improvement was seen in 87.2% of treated participants versus 23.6% receiving placebo. Nearly 90% of treated participants showed overall clinical improvement during the study.
The study's lead investigator, Dr. Jacobo Mintzer of the Medical University of South Carolina, said, "These results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia. Rarely do we see close to 90% of patients in a trial respond positively to a new medication."
He added, "Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression, and emotional distress that can profoundly impact patients and their caregivers. Current treatment options are limited and often carry significant side effects."
Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
Agitation affects the majority of people living with Alzheimer's disease and other dementias, especially in the advanced stages.
Symptoms may include pacing, aggression, yelling, restlessness, irritability, and emotional distress, making day-to-day care increasingly challenging.
It also places a heavy emotional and physical burden on caregivers. Many currently prescribed medications, including antipsychotics and sedatives, may increase the risk of falls, excessive sedation, stroke, or even death in older adults.
A treatment that safely reduces agitation without substantially increasing adverse events could be helpful for the patients as well as caregivers.
Investigators said that the results are the strongest seen so far in clinical trials on agitation in advanced dementia.
Also read: Alzheimer's May Be Detectable Years Before Symptoms, Says Neurology Expert
Dementia is an umbrella term describing a significant decline in mental function that interferes with everyday life. It commonly affects memory, thinking and reasoning abilities and is caused by underlying conditions such as Alzheimer's disease or vascular dementia.
Dementia significantly affects an individual's ability to live independently, work and perform daily activities while placing a substantial burden on families and caregivers.
According to the WHO, dementia costs the global economy an estimated US$1.3 trillion every year, with about half of that amount attributed to unpaid care provided by family members and friends.
© 2024 Bennett, Coleman & Company Limited